发明授权
- 专利标题: Antimycotic pharmaceutical composition
- 专利标题(中): 抗真菌药物组合物
-
申请号: US13258324申请日: 2010-04-09
-
公开(公告)号: US09050271B2公开(公告)日: 2015-06-09
- 发明人: Hirokazu Kobayashi , Eiko Kosugi , Nobuo Kubota
- 申请人: Hirokazu Kobayashi , Eiko Kosugi , Nobuo Kubota
- 申请人地址: JP Tokyo JP Tokyo
- 专利权人: POLA PHARMA INC.,NIHON NOHYAKU CO., LTD.
- 当前专利权人: POLA PHARMA INC.,NIHON NOHYAKU CO., LTD.
- 当前专利权人地址: JP Tokyo JP Tokyo
- 代理机构: Knobbe, Martens, Olson & Bear, LLP
- 优先权: JP2009-111549 20090409; JP2009-111550 20090409
- 国际申请: PCT/JP2010/056884 WO 20100409
- 国际公布: WO2010/117091 WO 20101014
- 主分类号: A61K31/4178
- IPC分类号: A61K31/4178 ; A61K9/70 ; A61K9/00 ; A61K9/08
摘要:
In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.
公开/授权文献
- US20120022120A1 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 公开/授权日:2012-01-26
信息查询
IPC分类: